AVTE Aerovate

Watchlist

2.430
+0.010+0.41%

Close Feb 28 16:00 ET

2.430
0.0000.00%

Post 16:16 ET

70.43MMarket Cap-0.81P/E (TTM)

About Aerovate Company

Aerovate Therapeutics, Inc. is a biotechnology company which engages in the development of drugs for rare cardiopulmonary disease. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension. The company was founded by Benjamin T. Dake on July 27, 2018 and is headquartered in Waltham, MA.

Company Profile

SymbolAVTE

Company NameAerovate

Listing DateJun 30, 2021

Issue Price14.00

Founded2018

CEOMr. Timothy P. Noyes

MarketNASDAQ

Employees51

Fiscal Year Ends12-31

Address930 Winter Street,Suite M-500

CityWaltham

ProvinceMassachusetts

CountryUnited States of America

Zip Code02451

Phone1-617-443-2400

Websitehttp://www.aerovatetx.com

Company Executives

Name
Position
Salary

Timothy P. Noyes
Director and Chief Executive Officer
3.07M

Dr. Marinus Verwijs, PhD
Chief Technical Officer
--

George A. Eldridge
Chief Financial Officer, Treasurer and Principal Accounting Officer
2.13M

Dr. Benjamin T. Dake, PhD
President, Chief Operating Officer and Secretary
--

Dr. Hunter Gillies, M.B.
Chief Medical Officer
--

Timothy J. Pigot
Chief Commercial Officer
2.45M

Ralph Niven,PhD
Chief Scientific Officer
--

Mark T. Iwicki
Chairman of the Board
218.30K

Donald J. Santel
Independent Director
568.54K

Dr. David S. Grayzel, M.D.
Independent Director
225.99K

Dr. Joshua Resnick, M.B.A.,M.D.
Independent Director
174.80K

Allison Dorval
Independent Director
185.80K

Habib Joseph Dable
Independent Director
363.25K

AVTE Aerovate

About Aerovate Company

Company Profile

Company Executives

Trending Stocks